In Vitro Activity of Arbekacin and Fosfomycin Against Methicillin-Resistant *Staphylococcus aureus* Clinical Isolates at Siriraj Hospital

Suwanna Trakulsomboon, Ph.D.,
Visanu Thamlikitkul, M.D.

**ABSTRACT**

In vitro activity of arbekacin and fosfomycin against 103 strains of methicillin-resistant *Staphylococcus aureus* (MRSA) isolated from different patients hospitalized at Siriraj Hospital, Bangkok, Thailand from 2006 to 2008 was determined by Kirby-Bauer disk diffusion method. The rates of susceptibility of MRSA to arbekacin and fosfomycin were 89.3 and 81.6 percent, respectively. The susceptibility of MRSA to arbekacin or fosfomycin was 94.2 percent. Arbekacin and fosfomycin may be alternative antibiotics for therapy of MRSA infections if the MRSA strains are susceptible. (*J Infect Dis Antimicrob Agents* 2009;26:11-7.)